CO2019006917A2 - New compounds as trigonal peptide agonists of the glp1 / glucagon / gip receptors - Google Patents

New compounds as trigonal peptide agonists of the glp1 / glucagon / gip receptors

Info

Publication number
CO2019006917A2
CO2019006917A2 CONC2019/0006917A CO2019006917A CO2019006917A2 CO 2019006917 A2 CO2019006917 A2 CO 2019006917A2 CO 2019006917 A CO2019006917 A CO 2019006917A CO 2019006917 A2 CO2019006917 A2 CO 2019006917A2
Authority
CO
Colombia
Prior art keywords
glucagon
trigonal
glp1
new compounds
gip receptors
Prior art date
Application number
CONC2019/0006917A
Other languages
Spanish (es)
Inventor
Torsten Haack
Michael Wagner
Andreas Evers
Dieter Kadereit
Martin Bossart
Katrin Lorenz
Stefania Pfeiffer-Marek
Martin Lorenz
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO2019006917A2 publication Critical patent/CO2019006917A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a agonistas trigonales de los receptores de GLP-1 / glucagón / GIP y a su uso médico, por ejemplo, en el tratamiento de trastornos del síndrome metabólico, incluyendo diabetes y obesidad, así como para la reducción del exceso de ingesta de alimentos.The present invention relates to trigonal agonists of GLP-1 / glucagon / GIP receptors and their medical use, for example, in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for the reduction of excess intake. food.

CONC2019/0006917A 2016-12-02 2019-06-27 New compounds as trigonal peptide agonists of the glp1 / glucagon / gip receptors CO2019006917A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306604 2016-12-02
PCT/EP2017/081125 WO2018100134A1 (en) 2016-12-02 2017-12-01 New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists

Publications (1)

Publication Number Publication Date
CO2019006917A2 true CO2019006917A2 (en) 2019-07-10

Family

ID=57542935

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0006917A CO2019006917A2 (en) 2016-12-02 2019-06-27 New compounds as trigonal peptide agonists of the glp1 / glucagon / gip receptors

Country Status (23)

Country Link
US (1) US10538567B2 (en)
EP (1) EP3548508B1 (en)
JP (1) JP7100033B2 (en)
KR (1) KR102576872B1 (en)
CN (1) CN110023329B (en)
AR (1) AR110300A1 (en)
AU (1) AU2017367173B2 (en)
BR (1) BR112019011228A2 (en)
CA (1) CA3045377A1 (en)
CL (1) CL2019001465A1 (en)
CO (1) CO2019006917A2 (en)
CR (1) CR20190313A (en)
DO (1) DOP2019000068A (en)
EA (1) EA201991345A1 (en)
EC (1) ECSP19046893A (en)
IL (1) IL266984A (en)
MA (1) MA46955A (en)
MX (1) MX2019006429A (en)
PE (1) PE20191143A1 (en)
PH (1) PH12019501216A1 (en)
TW (1) TW201833132A (en)
UY (1) UY37506A (en)
WO (1) WO2018100134A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201833131A (en) 2016-12-02 2018-09-16 法商賽諾菲公司 New compounds as peptidic glp1/glucagon/gip receptor agonists
TW201833132A (en) 2016-12-02 2018-09-16 法商賽諾菲公司 New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
BR112020020652A2 (en) 2018-04-10 2021-03-02 Sanofi-Aventis Deutschland Gmbh method for cleaving peptides bound to the solid phase from the solid phase
CN112218876B (en) 2018-04-10 2024-10-15 赛诺菲-安万特德国有限公司 Rixila Synthesis with end capping
UY38249A (en) 2018-05-30 2019-12-31 Sanofi Sa CONJUGATED PRODUCTS INCLUDING A TRIPLE GLP-1 / GLUCAGON / GIP RECEPTOR AGONIST, A CONNECTOR AND HYALURONIC ACID
WO2020130749A1 (en) * 2018-12-21 2020-06-25 한미약품 주식회사 Pharmaceutical composition comprising insulin and triple agonist having activity with respect to all of glucagon and glp-1 and gip receptor
US20230000950A1 (en) * 2019-10-04 2023-01-05 Hanmi Pharm. Co., Ltd. Composition comprising glucagon and glp-1 and gip receptor dual agonist and therapeutic use of same
AU2020384729A1 (en) 2019-11-11 2022-04-14 Boehringer Ingelheim International Gmbh NPY2 receptor agonists
TW202228762A (en) * 2020-01-30 2022-08-01 美商美國禮來大藥廠 Therapeutic uses of tirzepatide
MX2023001532A (en) 2020-08-07 2023-03-08 Boehringer Ingelheim Int Soluble npy2 receptor agonists.
US20240024426A1 (en) * 2020-08-14 2024-01-25 Hanmi Pharm. Co., Ltd. Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, glp-1, and gip receptors
CN114349828B (en) * 2020-11-27 2023-12-08 江苏师范大学 GLP-1/glucagon receptor dual agonist and application thereof
MX2023006281A (en) * 2020-12-16 2023-06-13 Zealand Pharma As Pharmaceutical composition of glp-1/glp-2 dual agonists.
JP2024524984A (en) * 2021-06-25 2024-07-09 イーライ リリー アンド カンパニー How to Treat Obstructive Sleep Apnea
KR20230004135A (en) * 2021-06-30 2023-01-06 한미약품 주식회사 Therapeutic use of a combination comprising a trigonal glucagon/GLP-1/GIP receptor agonist
WO2023228156A1 (en) * 2022-05-27 2023-11-30 D&D Pharmatech Inc. Peptide compositions and methods of use threof
WO2024067662A1 (en) * 2022-09-28 2024-04-04 广东东阳光药业股份有限公司 Glp-1/gcg/gip triple-receptor agonist and use thereof
CN117586374A (en) * 2023-10-07 2024-02-23 深圳湾实验室 GLP-1R/GIPR/GCGR triple agonist analogues and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517908A (en) 2002-10-02 2006-08-03 ジーランド・ファーマ・ア／エス Stabilized exendin-4 compound
US20080019911A1 (en) * 2005-04-20 2008-01-24 Aimin Xu Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4
PT1891105E (en) 2005-06-13 2012-06-27 Imp Innovations Ltd Oxyntomodulin analogues and their effects on feeding behaviour
EP2300035B1 (en) 2008-06-17 2015-08-12 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
PE20120914A1 (en) 2009-06-16 2012-08-22 Univ Indiana Res & Tech Corp GIP RECEIVER ACTIVE GLUCAGON COMPOUNDS
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
MX2013006304A (en) 2010-12-22 2013-07-02 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity.
CA2877358A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
MX356000B (en) 2012-06-21 2018-05-08 Hoffmann La Roche Analogs of glucagon exhibiting gip receptor activity.
AR092873A1 (en) 2012-09-26 2015-05-06 Cadila Healthcare Ltd PEPTIDES AS TRIPLE AGONISTS OF GIP, GLP-1 AND GLUGAGON RECEPTORS
UA116217C2 (en) * 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
PE20151239A1 (en) 2012-12-21 2015-09-08 Sanofi Sa DERIVATIVES OF EXENDIN-4 FUNCTIONALIZED
CN105829339B (en) 2013-11-06 2021-03-12 西兰制药公司 glucagon-GLP-1-GIP triple agonist compounds
TW201609797A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
EP3080151A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues
TW201625668A (en) * 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en) * 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TW201833132A (en) 2016-12-02 2018-09-16 法商賽諾菲公司 New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
TW201833131A (en) * 2016-12-02 2018-09-16 法商賽諾菲公司 New compounds as peptidic glp1/glucagon/gip receptor agonists

Also Published As

Publication number Publication date
US20180155406A1 (en) 2018-06-07
AU2017367173A1 (en) 2019-07-18
US10538567B2 (en) 2020-01-21
ECSP19046893A (en) 2019-07-31
KR102576872B1 (en) 2023-09-12
EP3548508A1 (en) 2019-10-09
UY37506A (en) 2018-06-29
AU2017367173B2 (en) 2022-03-24
CN110023329A (en) 2019-07-16
MX2019006429A (en) 2019-08-21
JP2019536796A (en) 2019-12-19
DOP2019000068A (en) 2019-05-31
IL266984A (en) 2019-07-31
CN110023329B (en) 2024-05-03
MA46955A (en) 2021-05-19
EA201991345A1 (en) 2019-11-29
PE20191143A1 (en) 2019-09-02
PH12019501216A1 (en) 2019-08-19
AR110300A1 (en) 2019-03-13
WO2018100134A1 (en) 2018-06-07
JP7100033B2 (en) 2022-07-12
KR20190085141A (en) 2019-07-17
EP3548508B1 (en) 2021-10-27
CR20190313A (en) 2019-09-11
TW201833132A (en) 2018-09-16
CL2019001465A1 (en) 2019-10-18
BR112019011228A2 (en) 2019-10-15
CA3045377A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
CO2019006917A2 (en) New compounds as trigonal peptide agonists of the glp1 / glucagon / gip receptors
UY36779A (en) NEW DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
AR099977A1 (en) DOUBLE PEPTIDE AGONISTS OF THE RECIPIENTS OF THE SIMILAR PEPTIDE TO GLUCAGON 1 (GLP-1) AND OF THE GLUCAGON RECEIVER (GCG), DERIVED FROM EXENDINA-4
UY35231A (en) Dual GLP1 / GIP or trigonal GLP1 / GIP / Glucagon agonists
BR112019011144A2 (en) compounds as glp1 / glucagon / gip receptor peptide agonists
BR112016022754A2 (en) exendin-4 derivatives as double peptide agonists of glp-1 / glucagon receptors
UY35072A (en) Exendin-4 derivatives as dual GLP1 / glucagon agonists
AR098741A1 (en) DUAL AGONISTS OF THE GLP-1 RECEIVER (PEPTIDE SIMILAR TO GLUCAGON 1) / GLUCAGÓN
CL2017001760A1 (en) Co-agonist compounds of gip and glp-1
AR098738A1 (en) ANALOGS OF THE EXENDINE PEPTIDE-4 NOT CLOSED
BR112016023039A2 (en) exendin-4-derived glp-1 / glucagon receptor dual agonists
AR102712A1 (en) INSULIN RECEPTOR PARTIAL AGONISTS
EA201690629A1 (en) COMPOUNDS THAT ARE REPRESENTED BY TRIPLE AGONISTS, GLUCAGON, GLP-1 AND GIP
UY34859A (en) Peptide analogs of exendin 4.
CO7400885A2 (en) Glucagon analogues
UA118558C2 (en) Peptide compound
CR20170376A (en) TREATMENT OF PEDIATRIC PATIENTS WITH MELLITUS DIABETES OF TYPE 2 WITH LIXISENATIDA
AR107282A1 (en) TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP)
AR103944A1 (en) TREATMENT OF PATIENTS WITH MELLITUS DIABETES TYPE 2